Colorectal Cancer

Adding oxaliplatin to conventional chemotherapy increases survival in patients with advanced colon cancer in a broad range of community practice settings.

Being newly diagnosed with lung or colorectal cancer is often not sufficient to motivate cigarette smokers to quit.

Patients who received cetuximab in combination with a standard adjuvant therapy treatment for colon cancer did not experience improved survival.

For patients with metastatic colorectal cancer that has progressed on multiple lines of standard therapy, regorafenib may be a new treatment option that achieves disease control.

Patients who are obese before being diagnosed with colorectal cancer are more likely to die of their disease than patients who are at a normal weight prediagnosis.

New findings suggest that increased serum glucose levels may be a risk factor for colorectal cancer in postmenopausal women.

Higher cancer fatalism, a term that refers to the belief that a cancer diagnosis leads inevitably to death, may be associated with a lower rate of colorectal cancer screening.

Men with colorectal cancer are not routinely informed about the potential for erectile dysfunction or how the condition can best be managed.

Medicare beneficiaries with CRC who made a higher number of visits to their PCP before their diagnosis had lower disease-related mortality and lower all-cause mortality.

Dr. Emily Chan, from Vanderbilt-Ingram Cancer Center, Discusses the VEGF-Trap Agent Aflibercept

The presence or absence of lymph node involvement has long been recognized as a critically relevant prognostic factor in solid tumor oncology.

Dr. Emily Chan from Vanderbilt-Ingram Cancer Center Discusses the Adjuvant Colorectal NO147 Trial

Dr. Axel Grothey from the Mayo Clinic Discusses Novel Agents for Colorectal Cancer

Colorectal cancer is the third most common type of cancer diagnosed in the United States and is the third most common cause of cancer-related death.

Investigators are recommending that black women follow a 'prudent dietary pattern' in lieu of a more Western-style diet to prevent the development of colorectal adenomas.

A look at the benefits of the chemoimmunotherapy rituximab for CLL and a look at the treatments and advances made in treating metastatic CRC.

A late phase metastatic colorectal cancer trial was stopped after demonstrating a statistically significant improvement in OS.

Aflibercept added to FOLFIRI chemotherapy improved PFS and OS in previously treated patients with metastatic colorectal cancer.

The iFOBT test examines the stool for hidden blood, which could come from anywhere in the GI tract, and possibly indicates a colon tumor or precancerous growths known as polyps.

A greater number of lymph nodes are being screened in colon cancer but this has not led to more diagnoses of node-positive colon cancer.

Adding oxaliplatin to 5-fluorouracil before and after surgery for the treatment of locally advanced rectal cancer is demonstrating significant benefit.

The field of immunotherapy is brimming with questions that researchers are working to answer, and many of those efforts were on display at the ASCO annual meeting.

Almost 1 in 3 adults in the United States do not get screened regularly.

A recent study showed that a patient-navigation-based intervention may help increase the rate of CRC screening in typically underserved groups, including low-income, ethnically diverse patients.

Dr. Howard Scher form Memorial Sloan-Kettering Cancer Center Discusses Circulating Tumor Cells